Last reviewed · How we verify
ASN007: ascending doses — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
ASN007: ascending doses (ASN007: ascending doses) — Asana BioSciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASN007: ascending doses TARGET | ASN007: ascending doses | Asana BioSciences | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASN007: ascending doses CI watch — RSS
- ASN007: ascending doses CI watch — Atom
- ASN007: ascending doses CI watch — JSON
- ASN007: ascending doses alone — RSS
Cite this brief
Drug Landscape (2026). ASN007: ascending doses — Competitive Intelligence Brief. https://druglandscape.com/ci/asn007-ascending-doses. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab